UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

THIS DOCUMENT RELATES TO:

The City of New York v. Abbott Laboratories, Inc., et al. S.D.N.Y. Case No. 04-CV-06054

County of Albany v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0425

County of Allegany v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-0236

County of Broome v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0456

County of Cattaraugus v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-0256

County of Cayuga v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0423

County of Chautauqua v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-0214

County of Chemung v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6744

County of Chenango v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0354

County of Columbia v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0867

County of Cortland v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0881

County of Dutchess v. Abbott Laboratories, Inc., et al. S.D.N.Y. Case No. 05-CV-6458

County of Essex v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0878

County of Fulton v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0519

MDL NO. 1456 Civil Action No. 01-12257-PBS

Judge Patti B. Saris

PLAINTIFFS' JOINT SURREPLY IN FURTHER OPPOSITION TO DEFENDANT DEFENDANTS PAR PHARMACEUTICAL COMPANIES, INC. AND PAR PHARMACEUTICAL, INC. INDIVIDUAL MOTION TO DISMISS County of Genesee v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-00267

County of Greene v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0474

County of Herkimer v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-00415

County of Jefferson v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0715

County of Lewis v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0839

County of Madison v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-00714

County of Monroe v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6148

County of Nassau v. Abbott Laboratories, Inc., et al. E.D.N.Y. Case No. 04-CV-05126

County of Niagara v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-06296

County of Oneida v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0489

County of Onondaga v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0088

County of Ontario v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6373

County of Orleans v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6371

County of Putnam v. Abbott Laboratories, Inc., et al. S.D.N.Y. Case No. 05-CV-04740

County of Rensselaer v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-00422

County of Rockland v. Abbott Laboratories, Inc., et al. S.D.N.Y. Case No. 03-CV-7055

County of Schuyler v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6387

County of Seneca v. Abbott Laboratories, Inc., et al.

1. 19.

W.D.N.Y. Case No. 05-CV-6370

County of St. Lawrence v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0479

County of Saratoga v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0478

County of Steuben v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6223

County of Suffolk v. Abbott Laboratories, Inc., et al. E.D.N.Y. Case No. 03-CV-12257

County of Tompkins v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0397

County of Ulster v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 06-CV-0123

County of Warren v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0468

County of Washington v. Abbott Laboratories, Inc., et al. N.D.N.Y. Case No. 05-CV-0408

County of Wayne v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-06138

County of Westchester v. Abbott Laboratories, Inc., et al. S.D.N.Y. Case No. 03-CV-6178

County of Wyoming v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-6379

10 . 10

County of Yates v. Abbott Laboratories, Inc., et al. W.D.N.Y. Case No. 05-CV-06172

Defendant Par Pharmaceutical Companies, Inc., and Par Pharmaceutical Inc., ("Par") have filed a reply memorandum that rests entirely on mischaracterization of plaintiffs' allegations, their opposition briefs (both the individual opposition filed in respect of Par's motion, and the Consolidated Opposition), ("Opp." and "Con. Opp.") and the law. Par ignores both the Par-specific allegations plaintiffs have set forth at ¶ 642-654 of the CC and the false AWPs and outrageous spreads set forth in Exhibit A and B to the CC. Rather, Par attempts to distract the Court by pointing to a summary allegation included by plaintiffs amongst their detailed Par allegations. Par's attempt to distract must fail as must Par's motion as a whole. Furthermore, Par apparently has no response to plaintiffs' discussion of Par's failure to abide by its obligation to report accurate prices to the government given Par's desire to have its drugs paid for by Medicaid. See Par Opp.at 3. Nor does Par respond to plaintiffs' admonition that Par mis-stated the reimbursement category of 3 of the 7 drugs it analyzed and that Par does not even know which of its own drugs are subject to a FUL. Id.

The CC and plaintiffs' oppositions make patently clear that plaintiffs have more than alleged a case of fraud against Par, satisfying all of this Court's prior rulings (notably, Par's individual motion does not attack any of plaintiffs' claims not subject to Fed. R. Civ. P. 9(b)). Par's motion to dismiss should be denied in its entirety.

I. Par Entirely Mischaracterizes Plaintiffs' Allegations of Wholesale Price Reporting Fraud and the Relevant Requirements articulated by this Court.

Par's reply ignores that plaintiffs' opposition sufficiently pled and complied with the particularity requirements of Fed. R. Civ. P. 9(b). Opp. at 2-3. Par's "core argument", that plaintiffs have failed to plead reliance on AWP is inaccurate. *First*, Plaintiffs have pled that where reimbursement is based on AWP, they relied on AWP. *Second*, Plaintiffs pled that where reimbursement is based on the FUL, they have relied on Par's price reporting to establish the FUL.

Contrary to Par's representation, these are not one sentence allegations. See Opp. at 2-3, 4, citing paragraphs 9, 12, 85-87, 122-136, 642-54, Exhibits A&B to the CC, and Exhibit A to Plaintiffs Opposition to Defendants' Consolidated Motion to Dismiss. Moreover, the allegations satisfy this Court's requirement that plaintiffs plead "a detailed overview of the fraudulent scheme that fits the paradigm described in the complaint." See Opp. at 2, quoting *In re Pharm. Indus. Average Wholesale Price Litig.*, 307 F. Supp.2d 196 at 210 (D. Mass. 2004)("*Pharm III*").

The weakness of Par's reliance point is made clear with its example of Dexamethasone. Par claims that plaintiffs provide no "basis to infer that any reimbursement based on an AWP of \$182.00 ever took place." Reply at 2. This is absurd. Dexamethasone is a non-FUL multisource drug. Thus, all of plaintiffs' pleadings directed at non-FUL drugs apply to Dexamethasone. Dexamethasone was always reimbursed at AWP, and Par set this AWP knowing it would be the basis of plaintiffs' reimbursement payments. CC at 646. Finally, the fact that Par simultaneously reported a WAC that may have been less misleading is irrelevant to Par's failure to "turn square corners" when reporting AWPs to the government and to plaintiffs' well-pled reliance on Par's intentionally reported false and inflated AWPs. See Opp. at 3.

II Plaintiff's Best Price and Rebate Allegations are Entirely Sufficient

Par concedes that plaintiffs "allege generally that reported Best Prices were incorrect because [Par] knowingly excluded factors that it was required by statute or contract to include in the Best Price calculations". Par then mistakenly argues that plaintiffs allege "no factual basis for their [best prices] claim" because plaintiffs do not satisfy 9(b). Reply at 3.

Par's argument misses the mark. First, it ignores that plaintiffs have alleged an unjust enrichment Best Prices claim. None of Par's objections based on 9(b)'s particularity requirement

¹ See Heckler v. Comty. Health Servs. of Crawford County, Inc., 467 U.S. 51, 62 (1984).

apply to plaintiffs' unjust enrichment claim. See Suffolk II at *2. Since Par makes no other objection to this claim, it should be sustained.

Par's sole remaining reason, therefore, in support of dismissal of plaintiff's Best Price rebate claims is that plaintiffs' claims lack the required specifics. (See Reply at 3). Plaintiffs' response is set forth at Point IV of their consolidated sur-reply opposition, which is incorporated herein.

Conclusion

For the reasons set forth herein and in Plaintiffs' Opposition Memorandum, Par's Motion to Dismiss should be denied in its entirety.

Dated: May 31, 2006.

Respectfully submitted,

City of New York and all captioned Counties except Nassau, by

KIRBY McINERNEY & SQUIRE, LLP

830 Third Avenue New York, New York 10022 (212) 371-6600

/s/ Joanne M. Cicala_

Joanne M. Cicala (JC 5032)

James P. Carroll Jr. (JPC 8348)

Aaron D. Hovan (AH 3290)

David E. Kovel (DK 4760) (pro hac vice

application pending)

For the City of New York

MICHAEL A. CARDOZO Corporation Counsel of the City of New York

John R. Low-Beer (JL 3755) Richard J. Costa (RC 7278) Assistant Corporation Counsels 100 Church Street, Room 3-162 New York, New York 10007 (212) 788-1007

LORNA B. GOODMAN

Peter J. Clines Rachel S. Paster Nassau County Attorney, by

MOULTON & GANS, P.C.

/s/ Nancy Freeman Gans
Nancy Freeman Gans, BBO # 184540

55 Cleveland Road Wellesley, MA 02481 Telephone: (781) 235-2246 Facsimile: (781) 239-0353

MILBERG WEISS BERSHAD & SCHULMAN LLP

Melvyn I. Weiss Michael M. Buchman Ryan G. Kriger One Pennsylvania Plaza New York, New York 10119-0165 Telephone: (212) 594-5300

Facsimile: (212) 868-1229

Special Counsel for the County of Nassau